Core Insights - Suzhou Huihan Medical Technology Co., Ltd. has completed a Series B financing round, exclusively funded by Jiangsu Runhuai Industrial Development Fund, aimed at expanding production capacity, automating upgrades, and fostering R&D innovation in its biomedical materials sector [2][6]. Company Overview - Established in 2005 and headquartered in Suzhou, Huihan Technology is an innovative enterprise that integrates technology, healthcare, and consumer attributes, focusing on the R&D and industrialization of biomedical materials [3]. - The company operates four main segments: high-end dressings, disposable surgical instruments, biomedical materials, and daily consumer products, driven by clinical needs and core technologies [3]. - Huihan Technology utilizes five core platforms: colloidal silver technology, hydrogel technology, bacterial cellulose technology, biological 3D technology, and MT technology, providing efficient and safe solutions for clinical medicine [3]. - The product range includes hemostatic, surgical sealing, anti-adhesion, and soft tissue management products, with over 50 medical device registrations, including two Class III medical devices [3]. Financing History - In 2017, during its Series A financing, Huihan Technology received investments from notable institutions such as Ningbo Huiding and Shanghai Jisong, primarily for technology R&D and market expansion [6]. - The recent Series B financing in 2025 will focus on the biomedical materials segment, emphasizing production capacity expansion, automation upgrades, and R&D innovation [6].